Cerity Partners LLC Grows Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Cerity Partners LLC raised its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 22.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,929 shares of the medical instruments supplier’s stock after purchasing an additional 2,333 shares during the quarter. Cerity Partners LLC’s holdings in AngioDynamics were worth $121,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ANGO. Quinn Opportunity Partners LLC purchased a new position in shares of AngioDynamics in the 4th quarter worth about $92,000. ProShare Advisors LLC acquired a new stake in shares of AngioDynamics in the fourth quarter valued at about $100,000. Graham Capital Management L.P. acquired a new stake in shares of AngioDynamics in the fourth quarter valued at about $106,000. OneDigital Investment Advisors LLC grew its stake in shares of AngioDynamics by 14.0% in the fourth quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier’s stock valued at $111,000 after buying an additional 1,490 shares in the last quarter. Finally, Nebula Research & Development LLC acquired a new stake in shares of AngioDynamics in the fourth quarter valued at about $125,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $9.12 on Wednesday. AngioDynamics, Inc. has a fifty-two week low of $5.83 and a fifty-two week high of $13.50. The business has a 50 day moving average price of $9.82 and a two-hundred day moving average price of $9.99. The firm has a market cap of $370.58 million, a PE ratio of -10.99 and a beta of 0.60.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The firm had revenue of $80.16 million during the quarter, compared to analyst estimates of $74.26 million. During the same quarter last year, the firm earned ($0.06) EPS. AngioDynamics’s quarterly revenue was up 13.0% on a year-over-year basis. On average, analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ANGO shares. Lake Street Capital started coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a “buy” rating and a $24.00 target price for the company. Canaccord Genuity Group increased their target price on AngioDynamics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, July 16th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of AngioDynamics in a research note on Wednesday, July 16th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.